# A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)

> **NCT02614716** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 32 (actual)

## Conditions studied

- Sjögren's Syndrome

## Interventions

- **DRUG:** LY3090106
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02614716
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-10
- **Primary completion:** 2018-09-05
- **Final completion:** 2018-09-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02614716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02614716, "A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02614716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*